Effects of montelukast combined with salbutamol on CysLTs,EOS,eotaxin,CD5L and ET-1 in children with bronchial asthma
This study was performed to analyze the changes in immune function,lung function and cysteinyl leukotrienes(CysLTs),eosinophil chemotactic factor eotaxin,CD5 antigen-like protein(CD5L),endothelin-1(ET-1)and whole-blood eosinophils(EOS)of the children with bronchial asthma after the treatment of montelukast combined with salbutamol.Total of 116 cases of children with bronchial asthma admitted to the Nanjing First Hospital from January 2022 to October 2023 were selected as study group,and were then randomly divided into salbutamol group and combined group,with 58 cases in each group,and 116 healthy children who underwent health checkups in the hospital were selected in a ratio of 1∶1 as healthy control group.The salbutamol group was given salbutamol aerosol,while the combined group was given salbutamol aerosol+montelukast chewable tablets for 2 weeks.The immune function and serum cytokine levels were compared between the healthy control group and the study group,and the time of clinical symptom relief,immune function,lung function indexes and serum cytokine levels were also compared between the salbutamol group and the combined group.Data showed that whole blood CD4+,CD4+/CD8+,and serum CD5L in the study group were lower than those in the control group(all P＜0.05),while the levels of whole blood CD8+,EOS,serum CysLTs,eotaxin,and ET-1 were higher than those in the control group(all P＜0.05).After 2 weeks of treatment,the duration of coughing,wheezing,dyspnea and lung rales in the combination group were shorter than those in the salbutamol group(all P＜0.05).After 2 weeks of treatment,whole blood CD4+,CD4+/CD8+,exertion lung volume(FVC),exertion expiratory volume in the first second(FEV1),FEV1/FVC and level of serum CD5L were elevated in the two treatment groups,as compared with pre-treatment,and these indexes in the combination group were higher than those in the salbutamol group(all P＜0.05);whole blood CD8+,EOS,serum CysLTs,eotaxin,ET-1 were decreased in both groups,and these indexes in the combination group were lower than those in the salbutamol group(all P＜0.05).Taken together,montelukast in combination with salbutamol could decrease the levels of serum CysLTs,eotaxin,ET-1 and whole blood EOS,while increase the level of serum CD5L in children with bronchial asthma,thus alleviating inflammation and improving immune and lung function of patients.
Bronchial asthmaMontelukastSalbutamolCysteinyl leukotrienesCD5 antigen-like protein
万方数据
维普
